Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Study Phase : Approved FDF
Sponsor : Lynch Regenerative Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration
Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.
Product Name : Regranex
Product Type : Protein
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Highest Development Status : Approved FDF
Sponsor : Lynch Regenerative Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Details : The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Product Name : Epidex
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 06, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
